Corbus Pharmaceuticals Holdings (CRBP)Orbimed Advisors LLC added to its stake +140K shares

1.74M

Shares reported · +140K vs prior quarter

0.33%

Disclosed portfolio weight

$16.3M

Reported value

Holdings as of

Mar 31, 2026

Filed

May 15, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Apr 1, 2026Company filing · Form 8-K · Executive change, Reg FDChanged a top executive or board member, and shared information with investors (and 1 more item)“On April 1, 2026, Corbus Pharmaceuticals Holdings, Inc. (the “Company”) was notified by Dominic Smethurst, the Company’s Chief Medical Officer, of his resignation, effective June 30, 2026.”
2. Apr 15, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On April 15, 2026, Corbus Pharmaceuticals Holdings, Inc. (the “Company”) entered into amended and restated employment agreements (the “Employment Agreements”), effective April 15, 2026, with certain of the Company’s executive officers: Yuval Cohen, Ph.D., Chief Executive Officer and Sean Moran, Chief Financial Officer.”
3. May 12, 2026Company filing · Form 8-K · Results, Reg FDReported its results, and shared information with investors
4. May 13, 2026Company filing · Form 8-K · Executive change, Shareholder voteChanged a top executive or board member, and held a shareholder vote (and 1 more item)“On May 13, 2026, the board of directors (the “Board”) of Corbus Pharmaceuticals Holdings, Inc. (the “Company”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Brent Pfeiffenberger, age 48, to serve as a member of the Board, thereby expanding the Board to seven members.”

What came next

1. May 19, 2026Company filing · Form 8-K · Material agreement, Executive changeChanged a top executive or board member, and signed an important agreement (and 1 more item)“On May 19, 2026, the Compensation Committee granted Brent Pfeiffenberger the following initial equity awards under the Corbus Pharmaceuticals Holdings, Inc. 2024 Equity Incentive Plan (the “2024 Plan”) in connection with his appointment to the Board: (i) a nonqualified stock option to purchase 24,700 shares of the Company’s common stock at an exercise price equal to the closing price of a share of common stock on…”
2. Jul 2, 2026Company filing · Form 8-K · Material agreement, Reg FDSigned an important agreement, and shared information with investors
3. Aug 6, 2026Company filing · Form 8-K · Results, Reg FDReported its results, and shared information with investors

How to read SEC Form 13F-HR

Form 13F is the quarterly report in which investment managers that oversee $100 million or more list the US-listed stocks and some other securities they held on the last day of the quarter.

Full guide: What is an SEC Form 13F?

What else is on file for Corbus Pharmaceuticals Holdings

OQRO holds no insider, Congress, fund or contract record for Corbus Pharmaceuticals Holdings dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its CRBP page.

How this filing works

• SEC Form 13F

Other disclosures at Corbus Pharmaceuticals Holdings

• SEC Form 13F-HRFeb 17, 2026
• SEC Form 4Jun 2, 2025
• SEC Form 4Jun 2, 2025
• SEC Form 4Mar 7, 2025
• SEC Form 4Feb 18, 2025
• SEC Form 4Feb 18, 2025

Everything OQRO holds on this company is on its CRBP page.